Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald S Robinson

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Clinical Psychiatry|March 17, 2009
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialKarl Rickels, Maria Athanasiou, Donald S Robinson, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderDonald S Robinson, Daniel K Kajdasz, Susan Gallipoli, et al.
The Journal of Clinical Psychiatry|December 29, 2007
Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trialsArif Khan, Kelly Schwartz, Chelsea Stern, et al.
Psychopharmacology Bulletin|November 17, 2007
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trialsDonald S Robinson, Michelle L Gilmor, Ying Yang, et al.
The Journal of Clinical Psychiatry|April 30, 2011
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorderArif Khan, Andrew J Cutler, Daniel K Kajdasz, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Clinical Psychiatry|March 17, 2009
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialKarl Rickels, Maria Athanasiou, Donald S Robinson, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderDonald S Robinson, Daniel K Kajdasz, Susan Gallipoli, et al.
The Journal of Clinical Psychiatry|December 29, 2007
Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trialsArif Khan, Kelly Schwartz, Chelsea Stern, et al.
Psychopharmacology Bulletin|November 17, 2007
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trialsDonald S Robinson, Michelle L Gilmor, Ying Yang, et al.
The Journal of Clinical Psychiatry|April 30, 2011
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorderArif Khan, Andrew J Cutler, Daniel K Kajdasz, et al.
Pageof 2